Covid-19 roundup: BeiGene snags rights to po­ten­tial an­ti­body treat­ment; Beef­ing up man­u­fac­tur­ing ops, Re­gen­eron adds 400 jobs at Irish fa­cil­i­ty

BeiGene snagged ex­clu­sive rights to de­vel­op and com­mer­cial­ize Sin­glomics Bio­phar­ma­ceu­ti­cals’ Covid-19 an­ti­bod­ies out­side of Greater Chi­na, thus ex­pand­ing the com­pa­ny’s search for a po­ten­tial treat­ment.

Un­der the li­cense agree­ment, BeiGene can de­vel­op, man­u­fac­ture and com­mer­cial­ize Sin­glomics’ DXP-593 and DXP-604 in “ex-Chi­na ter­ri­to­ry.” The Bei­jing-based biotech is set to be­gin a Phase I study in Aus­tralia next month, en­rolling up to 30 healthy vol­un­teers. A sec­ond multi­na­tion­al Phase I/II study is ex­pect­ed to be­gin by ear­ly Oc­to­ber in pa­tients with mild to mod­er­ate Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER